Tego Science, Inc. Logo

Tego Science, Inc.

Develops cell therapies for skin regeneration, 3D models for testing, and provides CDMO services.

191420 | KO

Overview

Corporate Details

ISIN(s):
KR7191420009
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙8로 93 (마곡동, 테고사이언스), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Tego Science, Inc. is a biopharmaceutical company specializing in advanced regenerative medicine, leveraging proprietary cell culture technology. Founded in 2001, the company develops, manufactures, and commercializes cell therapies for skin regeneration and wound healing. Its key approved products include Holoderm® for severe burns, Kaloderm® for diabetic foot ulcers, and Rosmir® for wrinkle improvement. Beyond therapeutics, Tego Science offers Neoderm®, a 3D cultured skin model as an alternative to animal testing, and provides Contract Development and Manufacturing Organization (CDMO) services from its GMP facility. The company maintains a robust R&D pipeline, with candidates like TPX-115 for rotator cuff tears, and operates a globally compliant allogeneic cell bank to ensure stable production of its innovative treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-05-27 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-05-26 00:00
Capital/Financing Update
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 111.0 KB
2025-05-23 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 108.1 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.1 KB
2025-03-19 00:00
Audit Report / Information
감사보고서제출
Korean 25.0 KB
2025-03-19 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.4 MB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.2 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 134.4 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.4 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 138.0 KB
2025-02-14 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-02-14 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청등결정) (회전근개 부분층 파열 개선을 위한 동종피부유래섬유아세포(TPX-11…
Korean 10.2 KB
2025-01-31 00:00
Regulatory News Service
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.0 KB

Automate Your Workflow. Get a real-time feed of all Tego Science, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tego Science, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tego Science, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden
ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland
SKT
OnKure Therapeutics, Inc. Logo
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America
OKUR
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan
4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel
OPK
OPKO HEALTH, INC. Logo
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America
OPK
Opthea Ltd Logo
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America
OPT
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea
131030
Opus Genetics, Inc. Logo
Developing gene therapies for inherited retinal diseases and other blinding conditions.
United States of America
IRD
ORAGENICS INC Logo
Biotech developing intranasal drugs for concussion and other brain disorders.
United States of America
OGEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.